

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 December 2023 (21.12.2023)



(10) International Publication Number
WO 2023/242238 A1

(51) International Patent Classification:

C12P 21/02 (2006.01) C12M 1/06 (2006.01)

C12N 15/79 (2006.01) C12M 1/34 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/065906

(22) International Filing Date:

14 June 2023 (14.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2208782.9 15 June 2022 (15.06.2022) GB

2215798.6 25 October 2022 (25.10.2022) GB

2300877.4 20 January 2023 (20.01.2023) GB

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; 60 Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: **BEN YAHIA, Bassem**; c/o UCB Biopharma SRL, 60 Allée de la Recherche, 1070 Brussels (BE). **DA-HOMAS, Thomas Aristide**; c/o UCB Biopharma SRL, 60 Allée de la Recherche, 1070 Brussels (BE). **EGGER-MONT, Stefanie J. M.**; c/o UCB Biopharma SRL, 60 Allée de la Recherche, 1070 Brussels (BE). **PIEDNOIR, Antoine Philippe Thomas**; c/o UCB Biopharma SRL, 60 Allée de la Recherche, 1070 Brussels (BE).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; c/o UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: CELL CULTURE PROCESSES

(57) Abstract: The present invention belongs to the field of the manufacture of recombinant proteins, particularly antibodies. More specifically, it relates to methods of producing recombinant proteins (such as antibodies) in a bioreactor and/or of increasing cell culture performance during the production of recombinant protein in bioreactors (N stage) via specific feeding strategy in the seed bioreactor (N-1 stage), namely by applying organised, operational stress during seed culture by increasing feeding speed, feeding quantity and/or increasing power input via impellers.

WO 2023/242238 A1